Long-term follow-up of otherwise healthy term infants with marked hyperbilirubinaemia: should the limits of exchange transfusion be changed in Turkey?

AIM: To evaluate prospectively non-haemolytic term infants with marked hyperbilirubinaemia treated by phototherapy only for evidence of bilirubin toxicity at 2-6 y of age, and to determine the suitability for Turkish children of the exchange transfusion limits recently reported by the American Academy of Pediatrics. METHODS: The study group included a total of 30 children, aged 2-6 y, who had developed marked hyperbilirubinaemia (20-24 mg dl(-1), 342-410 micromol l(-1)) during the newborn period (gestational age >37 wk, birthweight >2500 g) and were treated without exchange transfusion because intensive phototherapy, instituted during the preparations for exchange transfusion, was successful in decreasing their serum bilirubin levels. The control group consisted of 30 children of the same age group without clinical jaundice in the newborn period. Physical and neurological examinations, brainstem auditory-evoked potentials (BAEPs) and developmental tests for Turkish children were performed in both the study and control children. RESULTS: There was no difference between the groups with regard to mean BAEP latencies and developmental scores. None of the infants had hearing loss, developmental delay or abnormal neurological findings. CONCLUSION: The results suggest that successful intensive phototherapy without exchange transfusion in otherwise healthy term newborn infants with marked hyperbilirubinaemia (20-24 mg dl(-1), 342-410 micromol l(-1)) might not increase the risk of bilirubin brain injury and that the conventional limit of 20 mg dl(-1) (342 micromol l(-1)) could be changed to 22-24 mg dl(-1) (376-410 micromol l(-1)) for healthy term infants in Turkey. These limits, however, address only infants who do not have haemolytic disease, and the data are not sufficient to draw conclusions on the safety of even higher bilirubin levels (i.e. >24 mg dl(-1), 410 micromol l(-1)) in this population.

Long-term outcome of neonatal hyperbilirubinaemia: subjective and objective audiological measures.

Neonatal hyperbilirubinaemia is a common cause of early onset sensorineural hearing loss. There is no exact method to detect the extent of the neurotoxicity of bilirubin. On the other hand, the auditory pathway is known to be one of the most sensitive parts of the central nervous system (CNS) to this toxic agent. This prospective follow-up study was performed to evaluate and compare the factors related to the hearing of neonates with severe hyperbilirubinaemia and an age-matched control group. Both of these groups were tested using auditory brainstem response (ABR) as well as evoked otoacoustic emissions. Additionally, both of these groups of children were evaluated subjectively using an early speech-language-communication evaluation questionnaire. There was no significant difference in either objective (ABR and evoked otoacoustic emission) or subjective assessment (questionnaire) between the study and control groups. Furthermore, no correlation between serum total bilirubin levels and ABR latencies or thresholds was found within the study group.